On the other hand, there is no prospective evidence for the benefit of RCT in WHO grade II IDH-mut astrocytoma, since the analysis of the RTOG 9802 trial included all IDH-mut tumors without further subclassification. The gene discussed is IDH1; the disease is astrocytoma (excluding glioblastoma).